C04756: Early Diagnostic Biomarker for Acute Kidney Injury
Novelty:
Novel, early stage biomarker for easy diagnostic of acute kidney injury (AKI), acute renal failure (ARF) renal ischemia reperfusion injury, and/or ischemic acute tubular necrosis.
Value Proposition:
ARF is a syndrome with high mortality and morbidity, for which there is no specific therapy other than supportive care. There is a current lack of clinically feasible diagnostics preventing early detection of ARF, the existence of which would significantly improve the effects of supportive care. This technology utilizes a novel biomarker, Gro-, which is elevated very quickly in patients who are experiencing ARF amongst other kidney ailments. Additional advantages include:
• First biomarker for early diagnosis of ARF and associated diseases
• Time gained in providing supportive care earlier
• Reduced cost from preventing further disease development
• Gro- antibodies can be administered to patients suspected of AKI, thereby reducing risk of mortality through lung damage
Technical Details:
Johns Hopkins researchers have identified a novel and useful early diagnostic biomarker for ARF and associated kidney ailments. The biomarker Gro- is elevated in patients immediately after injury caused by ARF and associated kidney diseases. The amount of Gro- can be measured in tissue, serum, urine, in addition to several other body fluids. Comparisons can be done with control subjects with healthy functioning kidneys and statistical tests will determine whether an evaluation is significant or not, indicating the presence or absence of disease.
Looking for Partners:
To develop & commercialize the technology as better and more useful diagnostic for acute kidney injury and associated kidney diseases.
Stage of Development:
Pre-Clinical
Data Availability:
Animal data available with C57BL/6 mice.
Publications/Associated Cases: US 7833732 and WO 2007013919
